NCT00261365 - Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Unresectable Stage III or IV Malignant Melanoma

Interventions

DRUG

Ipilimumab

Solution, Intravenous, 3 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.

DRUG

Ipilimumab

Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.

Trial Locations (15)

43

Local Institution, Lima

5000

Local Institution, Odense C

8000

Local Institution, Aarhus C

47100

Local Institution, Forlì

47900

Local Institution, Rimini

48100

Local Institution, Ravenna

70126

Local Institution, Bari

72080

Local Institution, Jerusalem

90404

The Angeles Clinic And Research Institution, Santa Monica

92262

Comprehensive Cancer Center, Palm Springs

02215

Beth Israel Deaconess Medical Center, Boston

0310

Local Institution, Oslo

LIMA 11

Local Institution, Lima

413 45

Local Institution, Gothenberg

171 76

Local Institution, Stockholm